New drug MAR002 aims to tame acromegaly in early trial
Disease control
Not yet recruiting
This Phase 2 trial tests a new drug called MAR002 in 72 adults with acromegaly, a condition caused by a pituitary tumor that leads to too much growth hormone. Participants will receive either MAR002 or a placebo as injections under the skin. The study will check if the drug is sa…
Phase: PHASE2 • Sponsor: Marea Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC